The webinar will discuss the ATMP sector, why it is exciting from a technical point of view and what opportunities there are to utilise new and innovative regulatory pathways to get these medicinal products to market, whilst ensuring that the desire for innovation is balanced with the requirement for a robust commercial strategy.
This One Nucleus webinar will also explore how such critical path thinking impacts investment decisions and is factored into deal structure.
will be speaking alongside Dominic Schmidt from Syncona, discussing their thoughts around how the regulatory regime for ATMPs impact investment decisions and deal economics.
Registration is free and open to all. For more information, see the One Nucleus website.